BioXcel Therapeutics is trading at $0.10 (-17.62%) in pre-market amid continued pressure from its August 27, 2026 Chapter 11 filing and Nasdaq’s subsequent delisting decision.
- Chapter 11 overhang remains the primary company-specific catalyst; Nasdaq delisting and pending OTC migration increase liquidity and investor-risk concerns.
- Nasdaq said trading will be suspended at the September 8, 2026 open; shares are expected to move to the OTC Pink Limited Market, and the company does not intend to appeal.
- September 3, 2026 close: $0.12, following a 9.81% gain.